TABLE 1.
Baseline characteristics of the HBV–HCC and NBNC–HCC groups.
| Variable | HBV–HCC (n = 28) | NBNC–HCC (n = 26) | t/χ2 | p |
|---|---|---|---|---|
| Age (years) | 55.9 ± 11.5 | 59.5 ± 10.9 | −1.192 | 0.239 |
| Gender | 1.327 | 0.249 | ||
| Male | 24 (85.7) | 19 (73.1) | ||
| Female | 4 (14.3) | 7 (26.9) | ||
| Tumor size | 0.059 | 0.808 | ||
| <5 cm | 12 (42.9) | 12 (30.8) | ||
| ≥5 cm | 16 (57.1) | 14 (53.8) | ||
| Cirrhosis | 0.017 | 0.897 | ||
| Yes | 23(82.1) | 21(80.8) | ||
| No | 5(17.9) | 5(19.2) | ||
| Vascular invasion | 0.247 | 0.619 | ||
| Yes | 10 (35.7) | 11 (42.3) | ||
| No | 18 (64.3) | 15 (57.7) | ||
| Extrahepatic metastasis | 0.051 | 0.821 | ||
| Yes | 11 (39.3) | 11 (42.3) | ||
| No | 17 (60.7) | 15 (57.7) | ||
| ECGO PS | 0.044 | 0.835 | ||
| 0-1 | 18 (64.3) | 16 (61.5) | ||
| 2 | 10 (35.7) | 10 (38.5) | ||
| Child-Pugh class | 0.027 | 0.869 | ||
| A | 21 (75.0) | 20 (76.9) | ||
| B | 7 (25.0) | 6 (23.1) | ||
| BCLC stage, n (%) | 1.169 | 0.280 | ||
| B | 6 (21.4) | 9 (34.6) | ||
| C | 22 (78.6) | 17 (65.4) | ||
| Previous treatment | 0.974 | 0.968 | ||
| First-line | 9 (32.1) | 8 (30.8) | ||
| Second-line | 13 (46.4) | 10 (38.5) | ||
| Third-line or more | 6 (21.4) | 8 (30.8) | ||
| Laboratory parameters | ||||
| AFP | 0.350 | 0.554 | ||
| <400 ng/ml | 15 (53.6) | 16 (61.5) | ||
| ≥400 ng/ml | 13 (46.4) | 10 (38.5) | ||
| AST (U/L) | 42.1 ± 13.9 | 36.9 ± 16.1 | 1.268 | 0.210 |
| ALT (U/L) | 35.1 ± 20.3 | 29.0 ± 14.5 | 1.264 | 0.212 |
| ALB (g/L) | 39.8 ± 5.0 | 40.9 ± 5.3 | −7.490 | 0.457 |
| TBIL (µmol/L) | 18.1 ± 9.0 | 17.1 ± 8.2 | 0.460 | 0.648 |
| PT (s) | 12.62 ± 1.45 | 11.97 ± 1.01 | 1.907 | 0.062 |
Data in brackets represent percentages. HBV–HCC, hepatitis B virus-related hepatocellular carcinoma; NBNC–HCC, non-HBV; non-HCV, hepatocellular carcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; AFP, a-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; PT, prothrombin time.